Oragenics, Inc. (OGEN) Balance Sheet

The consistent contraction in total assets suggests that the company is consuming its capital base to fund ongoing research rather than building long-term value. This trend implies that the business quality remains highly speculative, as the balance sheet provides no cushion for operational delays or clinical setbacks.

While the current ratio of 133.42 appears high, it is largely a function of the company's minimal liability structure rather than robust liquidity. Investors should monitor the burn rate closely, as the current cash levels may necessitate further dilutive financing to maintain operations through the next fiscal year.

The negative trajectory of retained earnings highlights the absence of profitable operations and the reliance on external equity to offset continuous cash outflows. This structure suggests that shareholder value is being systematically eroded by the high cost of maintaining a pre-revenue biotechnology pipeline.